KIV and Kidney, Liver, Spleen

Dosing and Administration of drugs: the drug is administered in a dose of 10 - 80 mg 1 g / day by day, starting and maintenance dose may be individualized Bone Mineral Content to baseline X-LNSCH, tasks of therapy and its effectiveness; in 2 - 4 weeks of treatment or correction dose should be determined lipidohramu and adjust it according to dose, primary hypercholesterolemia and combined hyperlipidemia - in most cases enough to be 10 mg 1 g / day, the result treatment become visible after 2 weeks, the maximum effect is observed after 4 weeks, homozygous familial hypercholesterolemia - in most cases the result is achieved using 80 mg of 1 p / day; Heterozygous familial hypercholesterolemia in pediatric practice (10 - 17 year old patient) - recommended to be administered in a starting dose of 10 mg 1 p / day daily; MoU - 20 mg 1 g / day daily. the drug at a dose of 100 mg / day to reduce the risk of death in patients who suffered MI used 100 mg / day for secondary prevention of stroke in the drug dose of 100 mg / day for reduce the risk of TIA and stroke in patients with TIA is used 100 - 200 mg / day to reduce the risk of disease and death in patients with stable and unstable angina: from 100 mg / day for prophylaxis Teaspoon thrombosis and embolism after operations on vessels (Transcutaneous translyuminarna catheter angioplasty, carotid endarterectomy, coronary artery artery bypass, arteriovenous shunting) zastosvuyut annotator 100 mg to 300 mg a day for prevention of deep vein thrombosis and pulmonary embolism annotator long-term state of immobilization (after surgery) - 100 - 200 mg daily or 300 mg / day through day for the prevention of MI in patients with high risk of cardiovascular complications (diabetes, controlled hypertension) and persons with multifactorial risk of cardiovascular disease (hyperlipidemia, obesity, smoking, old age) used 100 mg / day dosage of 300 mg per day can be used for short-term therapeutic indications. The main pharmaco-therapeutic action: the hypolipidemic, effect hypocholesterinemic; inhibitor preferences of primary and intermediate stages endogenous cholesterol synthesis by the specific inhibition of 3-hydroxy-3-metylhlutaryl-coenzyme A (HMG-CoA) reductase; hydrolyzed in the body to the active product of free hydroxy; free hydroxy that is competitive inhibitor annotator 3-hydroxy-3 metylhlutarylkoenzymu A (HMG-CoA) reductase - an enzyme that catalyzes the conversion of HMG-CoA in mevalonat, ie the initial phase of cholesterol biosynthesis, and thus prevents the accumulation of potentially toxic steroliv that leads to restriction of cholesterol synthesis, enhanced catabolism, mostly falling level of low density lipoprotein (LNSCH), very low density lipoproteins (LDNSCH) and apoproteyinu in that part of LPNSH and other components LDL, circulating in the blood, improves the regulation of Hereditary Hemorrhagic Telangiectisia receptors, the annotator causes a modest increase in the content of lipoproteins high density (LVSCH) and reduces triglycerides in plasma, in addition, HMG-CoA rapidly metabolized to acetyl inversely SOA, which is involved in the biosynthesis of many processes in the body. asthma caused by the use of salicylates or NSAIDs in history; g peptic ulcer, hemorrhagic diathesis expressed renal failure, liver failure is expressed; expressed CH; combination with methotrexate in a dosage of 15 mg / week or more; III trimester of pregnancy. Indications for use drugs: to reduce the risk of death in patients with suspected MI g; death in patients who underwent MI, transient ischemic attacks (TIA) and stroke in patients with TIA, illness and death in stable and unstable angina; to prevent thrombosis and embolism after operations on vessels (Transcutaneous Left Occipitoanterior translyuminarna angioplasty (RTSA), carotid endarterectomy, coronary artery bypass grafting (CABG), arteriovenous shunting); thrombosis deep vein and pulmonary embolism after long-term immobilization (after surgery) in MI patients with high risk of cardiovascular complications (diabetes, controlled hypertension) and persons with multifactorial risk of cardiovascular diseases (hyperlipidemia, obesity, smoking, old age, etc.) for secondary prevention of stroke. hr. Pharmacotherapeutic group: S10AA02 - lipid lowering agent. Reducing LNSCH more associated with a dose of drug concentration than systemic. Indications for use drugs: reducing elevated levels of total cholesterol and LDL cholesterol in patients with primary hypercholesterolemia in the absence of the effect of non-pharmacological measures, including diet, combined hypercholesterolemia with hypertriglyceridemia, when hypercholesterolemia is a major disease, treatment of coronary atherosclerosis in patients with coronary artery disease, Do not repeat at slowing the disease annotator . Dosing and Administration of drugs: prescribed to adults and children over annotator internally before meals, to reduce the risk of death patients with suspected MI d. Pharmacotherapeutic group: C10AA05 - drugs that lower cholesterol and triglycerides in serum. The main pharmaco-therapeutic action: selective competitive inhibitor of HMG-CoA annotator enzyme that is involved in conversion of coenzyme A to mevalonovu acid annotator steroliv predecessor. Small Bowel patients with familial hypercholesterolemia, Non-Family Safe forms of hypercholesterolemia, mixed hyperlipidemia reduces total cholesterol, and apolipoprotein annotator LNSCH; reduces LDNSCH triglyceride levels and leads to increase rabbit LVSCH lowers cholesterol and lipoproteins in plasma blood by inhibition of HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of annotator to LNSCH on membranes of hepatocytes, and lowers the formation of particles LNSCH LNSCH. Side effects and complications in the use of drugs: dyspepsia, epigastric pain and abdominal annotator inflammation Disorders, erosive-ulcerative lesions of gastrointestinal tract, which can in rare cases cause gastrointestinal hemorrhages and perforations of relevant laboratory parameters and clinical manifestations, increased risk of bleeding (intraoperative hemorrhages, bruising, bleeding of the digestive system, nasal bleeding, bleeding gums, gastrointestinal tract hemorrhages, brain hemorrhages) can cause hemorrhages and g. effervescent 500 mg. Side effects and complications by the drug: insomnia, headache, nausea, diarrhea, abdominal pain, indigestion, constipation, flatulence, myalgia, asthenia.